Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment

Spritzer, Poli Mara; Motta, Alicia Beatriz

doi:10.1111/ijcp.12719

Cited by 29 publications

(32 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Its prevalence ranges between 5% and 10% (1). It is frequently correlated with metabolic abnormalities such as dyslipidemia, insulin resistance, type 2 diabetes mellitus (DM) and the metabolic syndrome, thus contributing to the pathogenesis of cardiovascular disease (2,3). Overt hypothyroidism has been linked to altered lipid profile and insulin insensitivity (4,5,6).…”

Section: Introductionmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: The impact of subclinical hypothyroidism on anthropometric characteristics, lipid, glucose and hormonal profile of PCOS patients: a systematic review and meta-analysis

Pergialiotis

Konstantopoulos

Prodromidou

et al. 2017

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Subclinical hypothyroidism (SCH) is encountered in 10-25% of women with PCOS. To date, it remains unclear whether this coexistence influences the severity of metabolic and hormonal profile of these patients. The purpose of our systematic review is to investigate this potential relation. Methods: We systematically searched Medline, Scopus, ClinicalTrials.gov, Cochrane Central Register of Controlled Trials (CENTRAL) and Google Scholar databases together with reference lists from included studies. All prospective and retrospective observational cohort studies that investigated the impact of subclinical hypothyroidism on hormonal and metabolic parameters of PCOS patients were included. The methodological quality of studies was assessed with the Ottawa-Newcastle criteria. Statistical meta-analysis was performed with the RevMan 5.3 software. Results: Twelve studies were finally included in the present review, which enrolled 2341 PCOS patients. Among them, 577 had subclinical hypothyroidism, whereas the remaining 2077 were PCOS women with normal thyroid function. The presence of SCH significantly affected HDL (MD -3.92 mg/dL 95% CI: -6.56, -1.29) and triglycerides levels (26.91 mg/dL 95% CI: -3.79, 50.02). HOMA-IR was also affected (MD 0.82 95% CI: 0.15, 1.50). On the other hand, LDL, fasting glucose and 2-h OGTT were not influenced. Similarly, prolactin, FSH, LH, LH/FSH ratio and sex hormone-binding globulin remained unaffected. Conclusion: Subclinical hypothyroidism does not influence the hormonal profile of women with PCOS. On the other hand, it results in mild metabolic abnormalities, which are not clinically important in a short-term setting.

show abstract

Section: Introductionmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: The impact of subclinical hypothyroidism on anthropometric characteristics, lipid, glucose and hormonal profile of PCOS patients: a systematic review and meta-analysis

Pergialiotis

Konstantopoulos

Prodromidou

et al. 2017

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…It should be considered that PCOS development risk factors include early menarche, early pubarche, low birth weight, and obesity. Also, early diagnosis of the syndrome in the pubescence period is very important due to the risk of endometrium carcinoma development, cardiovascular diseases, or diabetes type 2 in life later stages [11,[13][14][15][16][17].…”

Section: Diagnosismentioning

confidence: 99%

“…Disturbances in monthly menstruation regularity is found in 93% of PCOS women, including 68% of women revealing oligomenorrhoea, 21% with amenorrhoea, and 4% with primary amenorrhoea [12][13][14][17][18][19]. Frequent menstruation in PCOS women in the time interval below 21 days or rare menstruations over 35 days most often occur with impaired or anovulation [13,14,16,19]. The assessment of ovulation and menstruation in women in the reproductive period does not provide any problems -contrary to the pubescence period.…”

Section: Ovary Function Assessment In Pcosmentioning

confidence: 99%

“…Menstruations remaining irregular for over two years after menarche is a risk factor of menstruation disturbances in later periods of life [11,14,15,17]. In the first post menarche year, bleeding more frequently than every 20 days and more rarely than every 90 days is considered abnormal and calls for diagnostics [13][14][15]20]. After the first two years of menarche, in the majority of girls, the cycles are from 20 to 45 days.…”

Section: Ovary Function Assessment In Pcosmentioning

confidence: 99%

See 1 more Smart Citation

Stanowisko Polskiego Towarzystwa Endokrynologicznego, Polskiego Towarzystwa Ginekologów i Położników oraz Polskiego Towarzystwa Endokrynologii Ginekologicznej w sprawie diagnostyki i leczenia zespołu policystycznych jajników

Milewicz¹,

Kudła²,

Spaczyński³

et al. 2018

Endokrynologia Polska

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) diagnosis and therapy still arouse a lot of controversy. Each year brings new information, so, having collected the experience of three scientific societies, we present contemporary recommendations concerning PCOS diagnostics and treat-ment. In adult female diagnosis, we still use the Rotterdam criteria, which is two out of three of the follwing characteristics: a) ovulation abnormality, b) clinical or biochemical hyperandrogenism, and c) polycystic ovaries. In the case of teenagers, diagnostic criteria are as follows: menstruation disturbances two years after menarche and clinical or biochemical hyperandrogenism. The presence of polycysti-cally abnormal ovaries is not necessary. The consensus paper presents the threats resulting from imperfect diagnostic methods applied in PCOS (hyperandrogenism diagnostics, ultrasound examination of ovaries). Suggested therapy includes personalised schemes according to the dominant PCOS phenotype, i.e. metabolic, hyperandrogenic, or reproductive ones.

show abstract

“…Metformin, which enables the reduction of hyperandrogenism, is the drug of the first choice for the patients, including adolescents. [42][43][44].…”

Section: Therapeutic Managementmentioning

confidence: 99%

Polycystic ovary syndrome (PCOS) and the accompanying disorders of glucose homeostasis among girls at the time of puberty

Otto-Buczkowska

Grzyb

Jainta

2018

Pediatr Endocrino Diabetes Metab

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) usually arises during puberty and is marked by insulin resistance, hyperinsulinemia, and hyperandrogenism. The principle is that the diagnosis of PCOS must be based on the presence of at least two of the following three criteria: chronic anovulation, hyperandrogenism (clinical or biological), and polycystic ovaries. The diagnosis of PCOS in adolescents is particularly difficult due to developmental problems in this group. Many symptoms of PCOS, including acne, menstrual irregularities, and hyperinsulinemia, are common in normal puberty. Adolescents with PCOS are at an increased risk of developing health problems later on in life, such as diabetes, cardiovascular disease, and infertility. One should reckon with the frequent occurrence of the PCOS in type 1 diabetes, when the ovaries and the adrenals are exposed to excessive insulin concentrations. Ovarian hyperandrogenism is common in adolescent girls with type 1 diabetes. Methods of treatment for an adolescent with PCOS include diet and exercise. Metformin is commonly used in young girls and adolescents with PCOS as first-line monotherapy or in combination with anti-androgen medications. StreszczenieZespół policystycznych jajników (PCOS) zwykle pojawia się w okresie dojrzewania i charakteryzuje się występowaniem insulinooporności, hiperinsulinemii i hiperandrogenizmu. Przyjęta jest zasada, że diagnoza PCOS musi opierać się na obecności co najmniej dwóch z trzech następujących kryteriów: przewlekłego braku owulacji, hiperandrogenizmu (klinicznego lub biologicznego) i policystycznych jajników. Rozpoznanie PCOS u nastolatek jest szczególnie trudne. Wiele objawów PCOS, w tym trądzik, zaburzenia miesiączkowania i hiperinsulinemia, są częste w okresie dojrzewania. U nastolatek z PCOS istnieje zwiększone ryzyko wystąpienia problemów zdrowotnych w późniejszym życiu, takich jak cukrzyca, choroby sercowo-naczyniowe i niepłodność. Należy liczyć się z częstym występowaniem PCOS w cukrzycy typu 1, gdy jajniki i nadnercza są narażone na nadmierne stężenia insuliny. Hiperandrogenizm pochodzenia jajnikowego występuje często u nastolatek z cukrzycą typu 1. Leczenie młodzieży z PCOS obejmuje dietę i ćwiczenia fizyczne. Metformina jest powszechnie stosowana u młodych dziewcząt z PCOS w monoterapii pierwszego rzutu lub w połączeniu z lekami przeciwandrogenowymi. Słowa kluczowe hiperandrogenizm, zespół policystycznych jajników, insulinooporność, cukrzyca

show abstract

Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment

Cited by 29 publications

References 133 publications

MANAGEMENT OF ENDOCRINE DISEASE: The impact of subclinical hypothyroidism on anthropometric characteristics, lipid, glucose and hormonal profile of PCOS patients: a systematic review and meta-analysis

MANAGEMENT OF ENDOCRINE DISEASE: The impact of subclinical hypothyroidism on anthropometric characteristics, lipid, glucose and hormonal profile of PCOS patients: a systematic review and meta-analysis

Stanowisko Polskiego Towarzystwa Endokrynologicznego, Polskiego Towarzystwa Ginekologów i Położników oraz Polskiego Towarzystwa Endokrynologii Ginekologicznej w sprawie diagnostyki i leczenia zespołu policystycznych jajników

Polycystic ovary syndrome (PCOS) and the accompanying disorders of glucose homeostasis among girls at the time of puberty

Contact Info

Product

Resources

About